'In Europe — where Wegovy is not yet generally available in public health systems — 80 per cent of sales are paid for personally by consumers, with the remainder reimbursed by health insurance or states. In the US, more than 90 per cent of sales are completely or partially covered by health insurance, the company said.'

https://www.ft.com/content/bbbe8543-263c-4e5b-a567-2ef05f2b3138